Concepedia

Cefiderocol: A Novel Siderophore Cephalosporin Defeating Carbapenem-resistant Pathogens

Robert A. Bonomo

Clinical Infectious Diseases · 2019 · 57 citations · 11 references

DOIFull text

Open access

Concepts

Abstract

Cefiderocol, a novel siderophore cephalosporin in late-stage clinical development, utilizes a "Trojan horse" active transport mechanism to enter bacteria and has proven in vitro activity against carbapenem-resistant gram-negative pathogens, including those with major carbapenem-resistance mechanisms, and stability against all carbapenemases.

References

11

Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis

Evelina Tacconelli, Elena Carrara, Alessia Savoldi et al. · The Lancet Infectious Diseases · 2017 · 6.1K citations · Full text

, , +14

10 x '20 Progress--Development of New Drugs Active Against Gram-Negative Bacilli: An Update From the Infectious Diseases Society of America

Helen W. Boucher, George H. Talbot, Daniel K. Benjamin et al. · Clinical Infectious Diseases · 2013 · 696 citations · Full text

, , +14

The Role of Iron and Siderophores in Infection, and the Development of Siderophore Antibiotics

Malcom G P Page · Clinical Infectious Diseases · 2019 · 247 citations · Full text

, , +17

<i>In Vitro</i> Activity of the Siderophore Cephalosporin, Cefiderocol, against Carbapenem-Nonsusceptible and Multidrug-Resistant Isolates of Gram-Negative Bacilli Collected Worldwide in 2014 to 2016

Meredith Hackel, Masakatsu Tsuji, Yoshinori Yamano et al. · Antimicrobial Agents and Chemotherapy · 2017 · 234 citations · Full text

, , +16

Carbapenem-resistant Enterobacteriaceae colonization (CRE) and subsequent risk of infection and 90-day mortality in critically ill patients, an observational study

Thomas H. McConville, Sean B. Sullivan, Angela Gomez‐Simmonds et al. · PLoS ONE · 2017 · 216 citations · Full text

, , +12